Hepatocellular carcinoma (HCC) is a world-wide health problem. Poor and delayed diagnoses as well as high recurrence rate resulting in high mortality rate. In this study, we established a patient-derived xenograft (PDX) model from HCC patient, and continuously maintained with subcutaneous passage more than 20 times. This HCC PDX tumor exhibited the same histological characteristics with the HCC patient and could be used to verify therapeutic effect of liver cancer. We further evaluated this PDX model by experimental chemotherapy, demonstrating that this HCC PDX model was sensitive to sorafenib treatment. Further, the potential of natural killer cell-based immunotherapy for HCC was tested using this model. We found that NK92 cells effectively suppressed the tumor growth in vivo and prolonged the survival time of HCC-bearing PDX mice. This study indicates that HCC PDX model is a good platform to testify the efficacy of preclinical chemotherapy and immunotherapy.

中文翻译：

---

患者源性肝细胞癌异种移植模型的建立和临床前治疗。

肝细胞癌（HCC）是世界性的健康问题。诊断差和延迟以及高复发率导致高死亡率。在这项研究中，我们建立了来自肝癌患者的患者异种移植（PDX）模型，并通过皮下传代持续维持了20次以上。该HCC PDX肿瘤表现出与HCC患者相同的组织学特征，可用于验证肝癌的治疗效果。我们通过实验化学疗法进一步评估了该PDX模型，表明该HCC PDX模型对索拉非尼治疗敏感。此外，使用此模型测试了基于自然杀伤细胞的HCC免疫疗法对HCC的潜力。我们发现NK92细胞有效地抑制体内肿瘤的生长，并延长了携带HCC的PDX小鼠的存活时间。